Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT07197606
Starting soon Phase 2

Clinical Trial of Umbilical Cord Mesenchymal Stem Cells in Subacute Ischemic Stroke

NCT07197606 · tracked via the Priya Life Science China tracker
Sponsor
Shanghai IxCell Biotechnology Co., LTD
Phase
Phase 2
Started
2025-10-01
Last updated
2025-09-29

Condition(s) studied

Ischemic Stroke

Investigational drug(s) / intervention(s)

PlaceboIxCell hUC-MSC-S (Human Umbilical Cord Mesenchymal Stem Cells)

Placebo: Intravenous injection of placebo

IxCell hUC-MSC-S (Human Umbilical Cord Mesenchymal Stem Cells): Intravenous injection of IxCell hUC-MSC-S

Study summary

The goal of this clinical trial is to evaluate the efficacy, safety, and pharmacodynamic characteristics of Human Umbilical Cord Mesenchymal Stem Cells (hUC-MSCs) in adults with ischemic stroke in the anterior circulation during the recovery phase. Researchers will compare hUC-MSCs to a placebo to determine whether hUC-MSCs treatment is effective in treating recovery-phase anterior circulation ischemic stroke.

Eligibility

Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: * Age ≥18 years and ≤70 years, regardless of gender. * 14 to 90 days after ischemic stroke. * Clinical diagnosis of anterior circulation ischemic stroke. * National Institutes of Health Stroke Scale (NIHSS) score is 6-20 points (inclusive), with NIHSS motor arm (item 5) or motor leg (item 6) score of 2-4 points, and NIHSS level of consciousness item (1a) score \<2 points. * It was anticipated that participants would either be able to give informed consent or have a legal representative who could do so. Exclusion Criteria: * People who had a history of epilepsy, dementia, Parkinson's disease, severe depression, or other neurological or psychiatric disorders. * Intracranial hemorrhagic conditions. * Pre-stroke mRS score \>1. * Severe cardiovascular disease. * Severe pulmonary diseases.

Primary outcome measure(s)

  • Fugl-Meyer Assessment motor score — 12 months
    The Fugl-Meyer Assessment (FMA) is a stroke-specific, performance-based scale used to evaluate motor impairment. Its motor score, which ranges from 0 to 100, serves as a key parameter for quantifying motor recovery, where a higher score indicates better motor function.

Trial sites (1)

FacilityCityRegionStatus
Xuanwu Hospital, Capital Medical University Beijing Beijing Municipality

More Shanghai IxCell Biotechnology Co., LTD trials in China

Clinical Trial of Human Umbilical Cord Mesenchymal Stem Cells (IxCell hUC-MSC-P) in the Treatment of CTD-ILD Starting soon
Efficacy and Safety of IxCell hUC-MSC-O in Patients With Knee Osteoarthritis Recruiting

Other trials for the same condition

Improving Neuroprotective Strategy for Ischemic Stroke With Poor Recanalization After Thrombectomy by Intra-arterial TNK (INSIST-TNK) Recruiting
Direct Ischemic Conditioning for Endovascular Recanalization for Anterior Large Vessel Occlusion (DICER-aLVO) Recruiting
Probucol for Symptomatic Intracranial and Extracranial Artery Stenosis Recruiting
Precision Antithrombotic Therapy Enrolling by invitation
EndovascularTherapy Versus Standard Medical Terapy for Intracranial Large Vessel Occlusion in 24 Hours to 30 Days Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07197606 on ClinicalTrials.gov ↗ ← All trials in China